Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Former president’s spokesperson confirms Biden “rang the bell,” a tradition in cancer facilities to mark major milestones for ...

A major health update has been shared by the family of former president Joe Biden following the announcement of his ...

Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

Former President Joe Biden has given an update on his health following treatment for 'aggressive' prostate cancer.

Former President Joe Biden, 82, completed a round of radiation therapy for aggressive prostate cancer. He received treatment ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in ...

A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for ...

Dr. Timothy Eberlein, director of the Siteman Cancer Center based at Barnes-Jewish Hospital and WashU Medicine, says hospitals and cancer centers in the metro area are “providing tomorrow’s treatments ...